-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades Spruce Biosciences to Outperform, Announces $160 Price Target

Benzinga·12/03/2025 13:44:44
语音播报
Leerink Partners analyst Joseph Schwartz upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Outperform and announces $160 price target.